Table 1.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | TOTAL | Evidence level | |
---|---|---|---|---|---|---|---|---|---|---|
Amirthalingam et al. (2017) | Yes | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 6 | 1b |
Aube et al. (2020) | Yes | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 4 | 2b |
Brigatto et al. (2019) | Yes | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 1b |
Heaselgrave et al. (2019) | Yes | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 1b |
Radaelli et al. (2015) | Yes | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 6 | 1b |
Scarpelli et al. (2020) | Yes | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 4 | 2b |
Schoenfeld et al. (2019) | Yes | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2b |
Total | 4.714 |
Items in the PEDro scale: 1 = eligibility criteria were specified; 2 = subjects were randomly allocated to groups; 3 = allocation was concealed; 4 = the groups were similar at baseline regarding the most important prognostic indicators; 5 = measures of 1 key outcome were obtained from 85% of subjects initially allocated to groups; 6 = all subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least 1 key outcome were analyzed by “intention to treat”; 7 = the results of between-group statistical comparisons are reported for at least 1 key outcome; 8 = the study provides both point measures and measures of variability for at least 1 key outcome.